A new trading day began on Friday, with Allogene Therapeutics Inc (NASDAQ: ALLO) stock price up 14.77% from the previous day of trading, before settling in for the closing price of $1.49. ALLO’s price has ranged from $0.86 to $3.78 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 6.26%. Meanwhile, its annual earnings per share averaged 28.72%. With a float of $160.22 million, this company’s outstanding shares have now reached $223.16 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 28.71%, while institutional ownership is 50.55%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. In this transaction SVP, Chief Technical Officer of this company sold 786 shares at a rate of $1.22, taking the stock ownership to the 217,721 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 786 for $1.22, making the entire transaction worth $959.
Allogene Therapeutics Inc (ALLO) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.28 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.80% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Here are Allogene Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.88 in one year’s time.
